Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.65 |
| ▸ | BRPF1 | P55201 | 4/20 | 0.61 |
| ▸ | BRD4 | O60885 | 3/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.52 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.52 |
| ▸ | AHR | P35869 | 3/20 | 0.51 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.48 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | NQO2 | P16083 | 1/20 | 0.47 |
| ▸ | KLK7 | P49862 | 1/20 | 0.47 |
| ▸ | BRD1 | O95696 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | GALK1 | P51570 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31426215 | 1.00 | DAO (0.65) | DAOBRPF1BRD4CA12CA9 | |
| SCHEMBL29079027 | 0.79 | DAO (0.64) | DAOBRPF1BRD4CA12CA9 | |
| SCHEMBL30574135 | 0.79 | DAO (0.64) | DAOBRPF1BRD4CA12CA9 | |
| SCHEMBL30349848 | 0.78 | DAO (0.62) | DAOBRPF1BRD4CA12CA9 | |
| SCHEMBL21955107 | 0.78 | DAO (0.62) | DAOBRPF1BRD4CA12CA9 | |
| SCHEMBL8538250 | 0.78 | DAO (0.62) | DAOBRPF1BRD4CA12CA9 | |
| SCHEMBL1421868 | 0.78 | DAO (0.62) | DAOBRPF1BRD4CA12CA9 | |
| SCHEMBL31039545 | 0.78 | DAO (0.62) | DAOBRPF1BRD4CA12CA9 | |
| SCHEMBL29891722 | 0.78 | DAO (0.62) | DAOBRPF1BRD4CA12CA9 | |
| SCHEMBL28165616 | 0.78 | DAO (0.62) | DAOBRPF1BRD4CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295180-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| EP-4227304-A2 | THIADIAZOLE ANALOGS AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH A DEFICIENCY OF SMN MOTOR NEURONS | Novartis AG (CH) | 2023-08-16 | — | — | EP | disclosed |
| US-20230234950-A1 | CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| WO-2023006893-A1 | COMPOUNDS FOR THE TREATMENT OF PAIN, IN PARTICULAR NEUROPATHIC PAIN, AND/OR OTHER DISEASES OR DISORDERS THAT ARE ASSOCIATED WITH AT2R AND/OR AT2R MEDIATED SIGNALING | CONFO THERAPEUTICS N.V. (BE) | 2023-02-02 | — | — | WO | disclosed |
| CN-111196817-B | Tricyclic compounds as BRPF1 inhibitors | 四川大学华西医院 | 2021-06-11 | — | — | CN | disclosed |
| EP-3736271-A1 | THIADIAZOLE ANALOGS AND THEIR USE FOR TREATING DISEASES ASSOCIATED WITH A DEFICIENCY OF SMN MOTOR NEURONS | Novartis AG (CH) | 2020-11-11 | — | — | EP | disclosed |
| US-20200347045-A1 | CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2020-11-05 | — | — | US | disclosed |
| CN-111196817-A | Tricyclic compounds as BRPF1 inhibitors | 四川大学华西医院 | 2020-05-26 | — | — | CN | disclosed |
| US-20200115343-A1 | FUSED-BICYCLIC ARYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2020-04-16 | — | — | US | disclosed |
| US-10577329-B2 | Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors | FORMA THERAPEUTICS, INC. (US) | 2020-03-03 | — | — | US | disclosed |
| EP-3194375-A1 | PHENYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | Forma Therapeutics, Inc. (US) | 2017-07-26 | — | — | EP | disclosed |
| US-9624175-B2 | Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors | FORMA THERAPEUTICS, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-20160311774-A1 | FUSED-BICYCLIC ARYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. | 2016-10-27 | — | — | US | disclosed |
| WO-2016044782-A1 | PHENYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2016-03-24 | — | — | WO | disclosed |
| US-20150218175-A1 | THIADIAZOLE ANALOGS THEREOF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED-CONDITIONS | NOVARTIS AG (CH) | 2015-08-06 | — | — | US | disclosed |
| WO-2014116845-A1 | THIADIAZOLE ANALOGS THEREOF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED-CONDITIONS | NOVARTIS AG (CH) | 2014-07-31 | — | — | WO | disclosed |
| US-8653102-B2 | Substituted 2-oxo- and 2-thioxo-dihydroquinoline-3-carboxamides as KCNQ2/3 modulators | GRUENENTHAL GMBH (DE) | 2014-02-18 | — | — | US | disclosed |
| US-20120053206-A1 | Substituted 2-oxo- and 2-thioxo-dihydroquinoline-3-carboxamides as KCNQ2/3 modulators | GRUNENTHAL GMBH (DE) | 2012-03-01 | — | — | US | disclosed |
| EP-1485378-B1 | PIPERAZINYL-, PIPERIDINYL- AND MORPHOLINYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA NV (BE) | 2008-06-18 | — | — | EP | disclosed |
| EP-1485365-B1 | SULFONYL-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA NV (BE) | 2008-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234950-A1 | CRBN LIGANDS AND USES THEREOF | CRBN, CRKL, ERBB3 | DAO 3735/4885BRPF1 1576/4885BRD4 1883/4885 |
| US-20200347045-A1 | CRBN LIGANDS AND USES THEREOF | CRBN, CRKL, ERBB3 | DAO 3735/4885BRPF1 1576/4885BRD4 1883/4885 |
| US-20230295180-A1 | PROTEIN DEGRADERS AND USES THEREOF | MDM2, CUL1, PSMG3 | DAO 837/4885BRPF1 2350/4885BRD4 941/4885 |
| US-20160311774-A1 | FUSED-BICYCLIC ARYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | IDH1, IDH3A, IDH3B | DAO 975/4885BRPF1 1481/4885BRD4 135/4885 |
| US-20120053206-A1 | Substituted 2-oxo- and 2-thioxo-dihydroquinoline-3-carboxamides as KCNQ2/3 modulators | KCNQ1, KCNQ2, KCNQ3 | DAO 3432/4885BRPF1 2272/4885BRD4 191/4885 |
| US-10577329-B2 | Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors | IDH1, IDH3A, IDH3B | DAO 975/4885BRPF1 1481/4885BRD4 135/4885 |
| US-20150218175-A1 | THIADIAZOLE ANALOGS THEREOF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED-CONDITIONS | SMN1; SMN2, SF3B5, SF3B1 | DAO 2429/4885BRPF1 3791/4885BRD4 1785/4885 |
| US-20200115343-A1 | FUSED-BICYCLIC ARYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS | IDH1, IDH3A, IDH3B | DAO 975/4885BRPF1 1481/4885BRD4 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.